Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clotrimazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.97 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.97 |
| ▸ | CCKBR | P32239 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.97 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | GMNN | O75496 | 1/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | CA2 | P00918 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clotrimazole SCHEMBL1062253 | 0.98 | CYP19A1 (1.00) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| Clotrimazole SCHEMBL29358270 | 0.98 | CYP19A1 (1.00) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| Clotrimazole SCHEMBL3850 | 0.98 | CYP19A1 (1.00) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| Clotrimazole SCHEMBL6753811 | 0.97 | CYP19A1 (0.97) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| Clotrimazole SCHEMBL7647183 | 0.97 | CYP19A1 (0.97) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| Clotrimazole SCHEMBL12095111 | 0.97 | CYP19A1 (0.97) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| SCHEMBL9720736 | 0.95 | CYP19A1 (0.94) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| Clotrimazole SCHEMBL18916739 | 0.90 | CYP19A1 (0.84) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| SCHEMBL7160183 | 0.90 | CYP19A1 (0.84) | CYP19A1KCNN4NR1I2ADORA3TBXA2R | |
| Clotrimazole SCHEMBL27988836 | 0.90 | CYP19A1 (0.84) | CYP19A1KCNN4NR1I2ADORA3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412337-A4 | AZOLE COMPOUNDS AS ANTI-FUNGAL AGENTS | RANBAXY LAB LTD (IN) | 2004-12-22 | — | — | EP | disclosed |
| US-20040242896-A1 | Azole compounds as anti-fungal agents | SALMAN MOHAMMAD (IN) | 2004-12-02 | — | — | US | disclosed |
| EP-1412337-A1 | AZOLE COMPOUNDS AS ANTI-FUNGAL AGENTS | RANBAXY LABORATORIES, LTD. (IN) | 2004-04-28 | — | — | EP | disclosed |
| US-6710049-B2 | FUNGICIDES FOR AIDS, DIABETIC PATIENTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-03-23 | — | — | US | disclosed |
| EP-1347758-A1 | AZOLE COMPOUNDS AS ANTI-FUNGALS AGENTS | RANBAXY LABORATORIES, LTD. (IN) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003008391-A1 | AZOLE COMPOUNDS AS ANTI-FUNGAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2003-01-30 | — | — | WO | disclosed |
| US-20020119984-A1 | Fungicides for Aids, diabetic patients | RANBAXY LABORATORIES LIMITED (IN) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051408-A1 | AZOLE COMPOUNDS AS ANTI-FUNGALS AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119984-A1 | Fungicides for Aids, diabetic patients | CYP51A1, ERG28, CYP3A5 | CYP19A1 50/4885KCNN4 2282/4885NR1I2 3507/4885 |
| US-20040242896-A1 | Azole compounds as anti-fungal agents | ERG28, CYP51A1, DPM1 | CYP19A1 1262/4885KCNN4 4273/4885NR1I2 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.